- Home
- IBRX vs ACT Comparison
IBRX vs ACT Comparison
Compare IBRX & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | ACT |
|---|---|---|
| Founded | 2014 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 6.6B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IBRX | ACT |
|---|---|---|
| Price | $8.46 | $48.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | $12.57 | ★ $44.25 |
| AVG Volume (30 Days) | ★ 8.4M | 321.8K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 38.71 | 3.43 |
| EPS | N/A | ★ 2.42 |
| Revenue | $113,288,000.00 | ★ $1,235,827,000.00 |
| Revenue This Year | $88.59 | $4.06 |
| Revenue Next Year | $131.15 | $2.33 |
| P/E Ratio | ★ N/A | $20.03 |
| Revenue Growth | ★ 668.31 | 2.83 |
| 52 Week Low | $1.95 | $34.64 |
| 52 Week High | $12.43 | $50.56 |
Technical Indicators
Market Signals| Indicator | IBRX | ACT |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 45.37 |
| Support Level | $6.68 | $48.15 |
| Resistance Level | $8.51 | $48.79 |
| Average True Range (ATR) | 0.40 | 0.93 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 68.10 | 25.11 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.